Who makes GAd-209-FSP high dose?

GAd-209-FSP high dose is developed by Nouscom SRL.

What development phase is GAd-209-FSP high dose in?

GAd-209-FSP high dose is in Phase 1.

Last reviewed 2026-04-19 · How we verify

GAd-209-FSP high dose

Nouscom SRL · Phase 1 active Biologic

At a glance

Generic name	GAd-209-FSP high dose
Sponsor	Nouscom SRL
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GAd-209-FSP high dose CI brief — competitive landscape report
GAd-209-FSP high dose updates RSS · CI watch RSS
Nouscom SRL portfolio CI